IAEA Seeks Global Research Partners for Next-Generation Cancer Therapies

The IAEA believes the initiative will strengthen scientific capabilities in participating countries while expanding access to innovative radiopharmaceutical technologies.

The International Atomic Energy Agency (IAEA) is inviting research institutions worldwide to join a new scientific initiative aimed at developing advanced radiopharmaceutical technologies that could improve the diagnosis and treatment of cancer and other serious diseases.

The project builds on the growing success of radiotheranostics, an emerging field that combines medical imaging and targeted therapy into a single approach. Radiotheranostic treatments have already transformed care for certain cancers, including prostate cancer and neuroendocrine tumours, by helping doctors identify disease and deliver treatment more precisely.

Researchers now believe the next major breakthrough could come from creating radiopharmaceuticals that respond to specific conditions inside diseased tissues rather than relying solely on traditional receptor-based targeting methods. The new IAEA Coordinated Research Project (CRP), titled Development and Preclinical Assessment of Novel Stimulus-responsive Radiopharmaceutical Formulations, aims to support that transition and accelerate the development of more adaptable and effective treatment technologies.

Overcoming Limitations of Current Cancer Targeting Methods

Many of today's most widely used radiopharmaceuticals are designed to attach to specific receptors found on cancer cells. This approach has proven highly effective for certain tumour types. A challenge emerges when those receptors are absent, unevenly distributed or change over time. Many solid tumours display significant variation within different regions of the same tumour, making it difficult for conventional receptor-targeted treatments to consistently reach all cancer cells.

Scientists are increasingly exploring other characteristics that distinguish diseased tissues from healthy ones. These include factors such as low oxygen levels, increased acidity and abnormal enzyme activity, which are often present in cancerous environments. The proposed stimulus-responsive radiopharmaceuticals would remain inactive while circulating through the body and become activated only when they encounter specific biological conditions at the disease site. This approach could improve treatment precision while reducing unwanted effects on healthy tissues.

Researchers are also examining potential applications beyond cancer, including neurological and brain disorders where disease-specific microenvironments may offer new opportunities for targeted diagnosis and therapy.

Innovative Technologies Could Expand Treatment Possibilities

The project will investigate several advanced activation mechanisms, including systems that respond to pH changes, hypoxia and enzyme activity. Other technologies under consideration involve activation through external triggers such as light, ultrasound and magnetic fields.

Scientists will also study self-assembling and self-disassembling radiopharmaceutical systems that can change their structure inside the body to improve delivery and retention at disease sites. Another important area of research involves pre-targeting strategies for antibody-based radiopharmaceuticals. These methods seek to increase targeting accuracy while minimizing radiation exposure to healthy organs and tissues. The initiative is expected to support the exploration of emerging radionuclides that may offer new diagnostic and therapeutic capabilities. By encouraging innovation across multiple scientific disciplines, the programme aims to lay the groundwork for future generations of precision medicine.

Global Collaboration to Advance Radiotheranostics

The IAEA plans to bring together experts from a wide range of scientific fields, including radiochemistry, materials science, nanotechnology, pharmaceutical development and nuclear medicine. Participating institutions will collaborate on the design, synthesis and evaluation of novel radiopharmaceutical systems through coordinated laboratory studies and preclinical testing. Activities will include physicochemical characterisation, radiochemical assessments, cell-based experiments and animal model evaluations. Among the project's key objectives are developing standardised production protocols, validating uptake and retention mechanisms, obtaining proof-of-principle results in disease models and supporting the eventual translation of promising compounds into human clinical studies.

Institutions interested in participating are expected to demonstrate experience in drug delivery system development, expertise in radiolabelling techniques and access to medical radioisotopes such as technetium-99m, lutetium-177, zirconium-89, gallium-68 and fluorine-18. Access to suitable preclinical research facilities is also required.

The IAEA believes the initiative will strengthen scientific capabilities in participating countries while expanding access to innovative radiopharmaceutical technologies. By promoting knowledge exchange, training and international collaboration, the project seeks to create a strong scientific foundation for future advances in cancer diagnosis and treatment.